Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating GATT
- Conditions
- GenderContraception
- Registration Number
- NCT06230770
- Lead Sponsor
- University of California, San Diego
- Brief Summary
Gender diverse individuals who use gender-affirming testosterone therapy (GATT) to reduce gender dysphoria may also use progestins for contraception and to manage or suppress uterine bleeding. Research is limited, however, regarding expected bleeding patterns for individuals who choose to initiate GATT concurrently with a progestin. Clinicians who prescribe GATT do not have sufficient data to adequately counsel patients on side effects of concurrent progestin use and therefore extrapolate from studies conducted in cisgender women. This study is a prospective cohort study evaluating bleeding patterns and satisfaction among patients initiating GATT with or without concurrent initiation of a progestin contraceptive. The results from this study will enable clinicians to more accurately counsel patients using GATT on how the use of a progestin might affect their bleeding and whether this differs by progestin method.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 160
- English-speaking currently have a uterus and ovaries
- desire to initiate GATT
- potential desire to initiate a progestin (within 14 days of GATT initiation)
- previous gender-affirming surgery to remove their uterus and/or ovaries
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean days bleeding or spotting Start of GATT to 30 days mean number of days of bleeding or spotting during the 30 days after GATT initiation
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of California San Diego
🇺🇸San Diego, California, United States